QS Investors’s Vaxcyte PCVX Stock Holding History

QS Investors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,265	Closed	-$359K	–	1239
2020 Q3	$359K	Buy	+7,265	New	+$289K	﹤0.01%	849

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QS Investors's PCVX Position: Q4 2020 in Review

QS Investors sold out of Vaxcyte (PCVX) in Q4 2020, closing a stake of 7,265 shares — an estimated $359K sold.

QS Investors first reported a position in PCVX in Q3 2020 and held it in 1 quarter. The position peaked at $359K in Q3 2020. 83 funds tracked by Wall St. Rank hold PCVX as of Q4 2020.

QS Investors reported no remaining Vaxcyte position as of Q4 2020 after selling out during the quarter.
QS Investors sold 7,265 Vaxcyte shares in Q4 2020, an estimated $359K.
QS Investors first reported a position in Vaxcyte in Q3 2020 and held it in 1 quarter.
QS Investors's Vaxcyte position peaked at $359K in Q3 2020.
83 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.